Business Wire

Western Union and Italy’s Postepay Enable Cross-Border Payments

Share

Customers of App Postepay, among the preferred payment Apps in Italy, can now access Western Union’s cross-border and cross-currency platform to send money globally, following an agreement between Postepay, one of the largest Electronic Money Institution (EMI) in Italy, bringing together Poste Italiane’s assets and expertise in payments and telecommunications and Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement and payments.

More than seven million Postepay Evolution customers can now send money globally using Western Union via the Postepay App. They have the choice to fund their payments within the App using card or account and payout via Western Union’s Global Retail Network in over 200 countries and territories.

The integration of Western Union’s global cross-border, cross-currency money movement platform – including global settlement capabilities, network, compliance, and technology systems — enables international real-time cross-border transfers for financial institutions and service providers like Postepay, while globalizing services for their customers.

“It’s exciting to see two leading financial institutions working together to advance digital services for their customers by offering a seamless global cross-border payments experience,” said Hikmet Ersek, President and CEO, Western Union.

“Western Union’s open platform strategy allows us to innovatively connect the digital and physical worlds of money while helping leading organizations scale their services globally. We are delighted to welcome Postepay into the Western Union family,” he said.

Postepay SpA, a young company in the digital payments market, can count on a strong customer base of nearly 20 million of prepaid cards, more than 7 million of Postepay Evolution cards and more than 4,8 million of digital wallets. Postepay SpA is a center of excellence within the Poste Italiane Group.

“Postepay leads the country’s development and innovation by offering solutions that enable our customers to benefit from quality services and easy-to-use products,” said Marco Siracusano, Chief Executive Officer of Postepay.

“In line with our company’s strategy, Postepay’s first goal is to inform and guide changes in consumer habits while strongly investing and promoting our App based strategy. Therefore, the Postepay App offers our customer, not only highly performing dedicated services, but an ecosystem of integrated products and services which simplify transactions and exchanges at any level. Thanks to the collaboration with a leading brand such as Western Union our customers can now send money around the world in total comfort. In this context, a global leader such as Western Union, is the right partner to increase our growth,” he said.

“Summarizing the Postepay slogan, payments must be comfortable, simple and safe, and I believe that through this valuable partnership, we will be able to serve our respective customers even better,” concluded Marco Siracusano.

Remittances from Italy to the rest of the world in 2018 was USD 18.5 billion and into Italy USD 9.5 billion, according to the world bank.

WU-G

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of September 30, 2019, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2018, is available in 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.

About Postepay

Poste Italiane is one of Italy’s leading payment system providers, exploiting the Group’s integrated multichannel distribution platform based on its physical post office network and latest generation digital infrastructure. In 2018, the Company established Postepay SpA, the new company specializing in the development and processing of mobile and digital payments. Postepay SpA aims to consolidate its leadership and take advantage of the opportunities created by convergence between physical and digital channels, whilst at the same time supporting delivery of the Group’s overall strategy and guiding citizens, businesses and Public Administration entities through the transition from traditional payment systems to more advanced solutions. Postepay count on nearly 20 million of prepaid cards, more than 4,8 million e-wallets in use and nearly 4.5 million of SIM cards.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:

Western Union Communications
Global: Pia De Lima; pia.delima@wu.com / +1 954 260-5732
EU&CIS: Carolina Laurijssen; Carolina.laurijssen@wu.com / 44 (0) 7740 542 203

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye